Rare diseases
Investigational molecules
Locations
Safety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis
ItalyBempedoic acid in drug combination for patients with coronary artery disease without prior cardiovascular events
ItalyStudy of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer
ItalySwitch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer
ItalyEvaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A
ItalyA Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors
ItalyStudy of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive
ItalyStudy of MK-1045 alone or with tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy
ItalyCemsidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
ItalyPumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation
ItalyEIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer
ItalyDocetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment
ItalyTell us about your condition – we search every trial in Europe and connect you with the right site.
